GENE ONLINE|News &
Opinion
Blog

Ionis Pharmaceuticals
Ionis Pharmaceuticals’ Factor XI Reduction Proved Effective in Trial
2022-11-07
AstraZeneca Blocks Ionis’ Hypercholesterolemia Treatment from Moving into a Phase 3 Study
2022-09-23
Roche Receives Rights to Ionis’ Antisense Kidney Disease Drug for $55 Million
2022-07-12
AstraZeneca, Ionis’ ATTR Drug Edges Closer to US Approval With Latest Trial Win
2022-06-22
AstraZeneca, Ionis Close $3.5+ Billion Deal for Rare Protein Misfolding Disorder
2021-12-30
Ionis’ Once-Monthly Treatment for Rare Hereditary Disease Achieves Trial Endpoints
2021-03-31
JPM Healthcare Conference: Shape, Korro, and Ionis Present Advances in RNA Therapeutics
2021-01-18
Ionis Initiates Phase 3 Trials for Familial Chylomicronemia Syndrome Treatment
2020-12-06
Intellia Trials CRISPR Drug as Permanent Cure to Fatal Hereditary Disease
2020-10-21
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top